Welcome to Prospect - a support group for prostate cancer patients, their wives, partners and carers.
Prospect is run by prostate cancer survivors for the benefit of the communities in Bristol and surrounding districts

  • New chairman, and docks walk planned

    Tim Bond was elected chairman of Prospect at the 2021 AGM. He replaces Malcolm Gamlin, who retired after 13 years in the role. Malcolm was thanked for his hard work. Mick Broggio resigned as secretary so we are looking for a new one. Other committee members were re-elected.
    The next
    get-together is the Ashton Court walk on May 24. Meet 11am in courtyard cafe. Register with Chris Millett on 07721 436318. The annual docks walk is on July 2. Meet at Cottage pub 10am. Ring Ken Head on 0117 929 3156 to confirm. And Penny Brohn has invited us on Tuesday July 27 – 12.30 lunch to 4pm. Register by text (preferred) or ring Tim Bond on 07824 556 786. The October 8 walk at Lansdown might be ‘on’ too. Zoom ‘coffee mornings’ are on the first Thursday of the month (10-noon). Information by email beforehand. New patients and current members are all welcome. Newbies can contact us via Contact us (above) or our Tackle helpline (0800 035 5302).

    New vaccine ‘could prevent PCa’

    See here

    Dogs sniff out worst cancers

    Dogs can detect the most aggressive forms of PCa and could help develop a “robotic nose” to find the disease in the future, a study says. The dogs are said to have “enormous potential” (Feb ’21). More here. And it’s claimed daily coffee drinking lowers PCa risk, another study suggests (Feb ’21). More here

    Take part in surveys

    Prostate Cancer Research ask for your participation (from home) in surveys. People affected by PCa are instrumental in shaping what they do, so they’ve launched two patient-centred projects. They’re also running a special  survey with Ipsen UK&I to understand topics that patients find most tricky to talk about. More here

    Drugs to fight cancer resistance

    The world’s first drugs designed to stop cancer cells becoming resistant to treatment could be available within the next decade, scientists have said. A £75m investment to develop the drugs has been announced by the Institute of Cancer Research (Jan ’21). More here

    Urine test detects PCa

    A new technique detects PCa with almost 100% accuracy within 20 minutes using only a urine sample (Jan ’21). More here

    Bone scan breakthrough

    A new bone scan technique can identify men with advanced prostate cancer who’ll benefit from radiotherapy. This ground-breaking achievement could help extend the lives of 25-30% of such patients (Jan ’21). See more here

    Good news re Olaparib

    Olaparib has given new hope to men with incurable PCa, says the Daily Mail in this article.

    Big change in PCa diagnosis

    The biggest diagnostic development in PCa diagnosis for 50 years – that came about when NICE advised that all men at risk of PCa should have an MRI before a biopsy. The change has had a worldwide effect. See more here

    Cancer blood test trialled

    A new blood test which might be able to detect 50 cancers is being trialled by the NHS. More here. And two professors have made a discovery that could turn cancer into a treatable disease (Sept ’20). See more here. And minscule robots can seek out cancer.cells and destroy them More here

    Check your risk in 30 seconds!

    An online 30-second risk checker has been launched which men are encouraged to take –  see here And a Prostate Cancer Research team are using machine learning to develop a new way to classify PCa and separate the “tigers” from the “pussycats” (Sept ’20). More here And a US study demonstrated the highest accuracy to date in recognising and characterising PCa using artificial intelligence (July ’20). More here Also a new blood test for PCa is producing 99% accuracy – the best yet. More here And a new 15-minute ‘game-changing’ test is announced here

    Men set to lose out over abiraterone

    Prostate Cancer UK are extremely concerned that NICE is once again on the brink of rejecting abiraterone as a first-line treatment for men with high-risk advanced PCa. See more here  Earlier NICE had agreed to an appeal by Prostate Cancer UK to reverse its decision to restrict abiraterone for advanced PCa (Jul ’20). See more here. UK deaths from PCa exceeded 12,000 in 2019 for the first time and it overtook breast cancer as the most common cancer (June ’20). See more hereAnd a new type of immune cell which kills most cancers has been discovered. More info here  Screening: An expert explained why finding a suitable method is vital but is difficult. More here

  • Hormone treatment and Covid-19

    Hormone treatment might offer some protection from Covid-19, it’s reported. See more here But it can make PCa worse, this study finds.  An online survey aiming to shed more light on the experience of PCa patients on this therapy (aged 35 to 80) is being conducted via this link And a London college has developed an online intervention to support men with PCa who have ongoing fatigue, and it is recruiting patients to take part. Information here. And an oil-based oral formulation has been found that not only enables a smaller dose of abiraterone to be effective but also has the potential to dramatically reduce possible side effects (Jun ’20). See more here

  • Chemo swapped for precision drugs

    Advanced PCa patients can take enzalutamide or abiraterone at home instead of going into hospital for chemotherapy, NHS England says. It will relieve pressure on the NHS. The drugs are smarter, kinder treatments and could extend the lives of many more men, it’s said (May ’20). See more here: And a new treatment is being tested that could extend the lives of men with advanced prostate cancer, by killing cancer in the prostate despite the disease having spread. The nationwide Atlanta trial, at Imperial College London, was recruiting 918 newly-diagnosed men. Read more here.  And positive results have been reported from a trial that tested the PARP-inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant PCa who have alterations in certain DNA damage repair genes. Roughly 20-30% of these patients harbour these gene mutations in their tumours and thus may benefit from olaparib.

  • Cancer can be detected much earlier

     

    The first signs of cancer can appear decades before diagnosis, scientists have found – a discovery that could revolutionise treatment (Feb ’20). See more here. And Public Health England has published a statistical bulletin on survival rates for many types of cancer based on recent data. It stressses the importance of early diagnosis. A summary is here with a link to the full report

  • Patient guide ‘good source of info’

    Prostate Cancer Foundation’s 2019 Patient Guide is said to be one of the best sources of information from diagnosis to survival of PCa. Download it for free here.  Our New Research page is updated regularly.

  • Drugs approved and a PCa ‘killer’

    The NHS confirmed that the chemotherapy drug docetaxel will be made available to PCa patients as soon as they are diagnosed instead waiting until other treatments stop working. See.  And NICE has approved a new drug, Darolutamide, as an option for treating hormone-relapsed PCa in men at high risk of developing metastatic disease. See more here Also scientists have found that a natural insecticide kills advanced PCa cells. See more here More news on the newsletter page.

RunningWe are a friendly and supportive network that usually meets at BAWA, Filton. Because of COVID-19, meetings are held via Zoom. Meeting details are in the column on the left. Our group aims to:

We have found that knowledge is of great benefit to the patient. It enables him to play an active part in the decision-making process, for example in selecting the best treatment.

We offer a friendly welcome – join us

Are you just diagnosed, or do you suspect that you may have prostate cancer? Then for friendly peer support and an introduction to Prospect email prospect.bristol@gmail.com or call the Tackle helpline, which will put you in touch with us: 0800 035 5302. You can join us for a small subscription by filling in the PDF membership form on the Contact/Join us page.

This site has been compiled by prostate cancer survivors. We do not claim to have specialist knowledge other than that gained by prostate cancer patients during their treatment.

Regional co-ordinator needed

Tackle need a Regional Co-ordinator for Western Counties. The holder acts as a focal point for communications on region-specific topics between the new chairman, Ken Mastris, and member groups in the area. In addition, he or she will participate in occasional meetings or teleconferences. All expenses are reimbursed. If any Prospect member wishes to volunteer, they can email info@tackleprostate.org

Protected from despair…

George Monbiot writes in the Guardian that the principles that define a good life protect him from despair, despite a diagnosis of prostate cancer and the ‘grisly’ operation he faces (Mar ’18). See here

We give illustrated talks

Our Mike Broxton gives prostate cancer awareness talks to interested groups, including those with learning disabilities. To arrange a talk, contact prospect.bristol@gmail.com or 0800 035 5302.

Having the conversation…

“Manversation” is a campaign to encourage men to speak about prostate cancer, particularly the advanced prostate form. Tackle have collaborated with Orchid, the male cancer charity, and put their name to a video and supporting material on the Manversation website.

Myths debunked and spotting fake cancer news

Ten cancer myths debunked. See here. And also here are six tips to spot cancer fake news

New information for at-risk black men

One in four black men will get prostate cancer – double the overall risk faced by all UK men. Are you are risk? See here

Energise wins award

The exercise-based cancer rehab programme Energise won the Together We Achieve award for 2016. The award, announced at the inaugural Health & Care Awards in March ’17, recognises teams working together to deliver improved patient care and public health. See a video about their work here. For more information on Energise see our Helpful links page.

New research strategy launched

Prostate Cancer UK has launched an ambitious 10-year strategy setting out how it will invest in the most innovative research to create a step change in our knowledge of prostate cancer. See here. And we have more research news here.

Swedish test shows promise

Swedish researchers found a test which is a potentially a game-changing step forward for prostate cancer risk assessment.

It involved genetic and protein biomarkers (the S3M) and was much better than PSA alone at detecting potentially dangerous prostate cancers. The Swedish results give compelling evidence the S3M risk assessment model can

dramatically cut the number of unnecessary biopsies, without compromising patients’ safety. But Prostate Cancer UK says it’s going to be important to validate this study in a more diverse population before it can accept that it will work elsewhere. It is funding more research to develop a new UK risk assessment tool. These plans are still going full steam ahead, and PCa UK expects to have more to say about this later. See more here.

Tiger or pussycat? That’s the problem

It’s a big problem to tell the difference between slow-growing cancers and aggressive ones. See here. But new research from one of Prostate Cancer UK’s Centres of Excellence could help identify which is which (Oct ’17). See here.

Cancer ‘as unique as fingerprints’

Each person’s cancer is as unique as their fingerprints, said Professor Gillies McKenna, Director of the CRUK/MCR Oxford Institute for Radiation Oncology. This created an opportunity for more precise treatment.

Back to top

  • Know your risk

    Prostate Cancer UK has a new infographic and booklets.

    Exchange information

    www.myprostate.eu is now also available in English and prostate cancer patients can exchange information and help each other with treatment decisions.

  • Help with treatment choices

    Get enhanced guidance on treatment options, thanks to a checklist developed by researchers (Jun ’17). See. More help here. And why it’s difficult to choose among treatment options (Jul ’17). See. Men with early stage prostate cancer wishing to preserve sexual function while on treatment do not always make the right choices. See

  • Buddies home support hit

    This Macmillan service offered support for adult cancer patients in their homes in our areas but due to Covid they can’t visit people in their homes. The Bristol Buddies service has moved across into its national telephone service for now. Ring 07543 248714 or email bristolbuddies@macmillan.org.uk